<DOC>
	<DOCNO>NCT01109407</DOCNO>
	<brief_summary>Background : - Multiple myeloma type cancer affect white blood cell poor long-term survival rate . Two type cancer , monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma ( SMM ) , may eventually progress develop multiple myeloma . Researchers interested collecting sample individual diagnose MGUS SMM study possible risk factor develop multiple myeloma . Objectives : - To study risk factor may cause MGUS SMM progress multiple myeloma . Eligibility : - Individuals least 18 year age diagnose either MGUS SMM multiple myeloma . Design : - Participants examine study researcher initial visit , 6 month follow enrollment , every 12 month maximum 5 year . - The following test may perform : ( 1 ) blood urine test , ( 2 ) bone marrow aspiration biopsy , ( 3 ) imaging study , ( 4 ) skeletal survey ( series skeletal X-rays skull , spine , pelvis , rib , shoulder , upper arm , thigh bone ) . - Treatment provide part protocol . - Participants remain study 5 year , MGUS SMM progress multiple myeloma require treatment .</brief_summary>
	<brief_title>Natural History Study Monoclonal Gammopathy Undetermined Significance ( MGUS ) Smoldering Myeloma ( SMM )</brief_title>
	<detailed_description>Background : - Multiple Myeloma ( MM ) incurable plasma cell neoplasm median survival 3-4 year . - Monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma ( SMM ) premalignant plasma cell proliferative disorder characterize elevated monoclonal protein bone marrow plasma cell . MGUS affect 3.2 % Caucasians age 50 1 % annual risk progression MM . approximately 3000 case SMM diagnose annually 10 % annual risk progression MM . - Current risk stratification scheme rely serum protein marker phenotyping flow cytometry . While differentiate high low risk patient , predict outcome individual patient , integrate one another , limited direct correlation biology . - Paired sample link clinical information advance research improve risk stratification , pathogenesis MGUS , SMM , MM , potential early treatment window incurable disease . Objectives : - To characterize natural history prognosis MGUS SMM - To integrate protein marker ( include immunoglobulin free light-chains ) immunophenotyping flow cytometry molecular profile ( include gene expression profile ) clinical outcome - To apply expertise diagnostic technology provide improve evaluation , monitoring , risk-stratification patient protocol - To provide paired sample blood tissue link clinical molecular information pilot translational study Eligibility : - A confirmed diagnosis MGUS SMM ( base IMWG diagnostic criterion ) - Age great equal 18 year - ECOG performance status range 0-2 - Patients diagnosis MM eligible study . Design : - This prospective cohort study patient either MGUS SMM . - Following initial evaluation confirmation diagnosis , patient follow clinically indicate , usually 12 month interval . - The primary endpoint progression MM require treatment . - Patients may donate cellular product tissue appropriate research purpose . 154 patient MGUS 154 patient SMM enrol protocol .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis MGUS SMM make accordance clinical diagnostic criterion set forth International Myeloma Working Group ( Table 1 ) . The diagnosis confirm either serum/urine protein electrophoresis , immunofixation lightchain assay ; immunohistochemistry analyse bone marrow biopsy , combination test . Age great equal 18 year . ECOG performance status 02 . The patient must competent sign inform consent form . EXCLUSION CRITERIA : A diagnosis MM define patient detectable Mprotein blood and/or urine , monoclonal plasma cell bone marrow , evidence endorgan damage ( base International Myeloma Working Group diagnostic CRAB criterion : hypercalcemia [ serum calcium least 1 mg/dL upper limit normal ] , renal failure [ creatinine great 1.95 mg/dL ) , anemia ( hemoglobin le 10 g/dL ] , bone lesion [ lytic lesion osteoporosis compression fracture ] ) . Patients receive previous therapy MM .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 26, 2016</verification_date>
	<keyword>Plasma Cell Neoplasm</keyword>
	<keyword>Natural History</keyword>
	<keyword>Translational Studies</keyword>
	<keyword>Gene Expression Profiling</keyword>
	<keyword>Protein Markers</keyword>
	<keyword>Smoldering Myeloma</keyword>
	<keyword>SMM</keyword>
	<keyword>Monoclonal Gammopathy Undetermined Significance</keyword>
	<keyword>MGUS</keyword>
</DOC>